Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 6, 2013, Pages 2780-2787

  Svensson, Elin M ^a   Aweeka, Francesca ^b   Park, Jeong Gun ^c   Marzan, Florence ^b   Dooley, Kelly E ^d   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; EFAVIRENZ;

ADULT; ARTICLE; COMPARTMENT MODEL; CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STEADY STATE; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BENZOXAZINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MIDDLE AGED; MODELS, BIOLOGICAL; QUINOLINES; STOCHASTIC PROCESSES; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 84877861235     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00191-13     Document Type: Article

References (39)

1. World Health Organization. 2012. Global tuberculosis report 2012. World Health Organization, Geneva, Switzerland.
2. World Health Organization. 2012. Global tuberculosis report 2012. World Health Organization, Geneva, Switzerland. 2. Kwan CK, Ernst JD. 2011. HIV and tuberculosis: A deadly human syndemic. Clin. Microbiol. Rev. 24:351-376.
3. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugyenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I, AIDS Clinical Trials Group Study A5221. 2011. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N. Engl. J. Med. 365:1482-1491.
4. McIlleron H, Meintjes G, Burman WJ, Maartens G. 2007. Complications of antiretroviral therapy in patients with tuberculosis: Drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J. Infect. Dis. 196(Suppl 1):S63-S75. doi:10.1086/518655.
5. Koul A, Dendouga N, Vergauwen K, Molenberghs B, Vranckx L, Willebrords R, Ristic Z, Lill H, Dorange I, Guillemont J, Bald D, Andries K. 2007. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3:323-324.
6. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227.
7. Huitric E, Verhasselt P, Andries K, Hoffner SE. 2007. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother. 51:4202-4204.
8. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. 2010. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother. 54:1022-1028.
9. Zhang T, Li SY, Williams KN, Andries K, Nuermberger EL. 2011. Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 184:732-737.
10. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V. 2011. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One 6:e17556. doi:10.1371/journal.pone.0017556.
11. Shang S, Shanley CA, Caraway ML, Orme EA, Henao-Tamayo M, Hascall-Dove L, Ackart D, Lenaerts AJ, Basaraba RJ, Orme IM, Ordway DJ. 2011. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob. Agents Chemother. 55:124-131.
12. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, McNeeley DF. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360:2397-2405.
13. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF. 2012. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrugresistant tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother. 56:3271-3276.
14. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, De Marez T, van Heeswijk R, Kerstens R, Koul A, De Beule K, Donald PR, McNeeley DF. 2008. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:2831-2835.
15. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. 2006. Combinations of R207910 with drugs used to treat multidrugresistant tuberculosis have the potential to shorten treatment duration. Antimicrob. Agents Chemother. 50:3543-3547.
16. Janssen Pharmaceutical Companies. 28 November 2012. Briefing document, TMC207 (bedaquiline), treatment of patients with MDR-TB, NDA 204-384. Janssen Pharmaceutical Companies, Titusville, NJ.
17. Mesens N, Verbeeck J, Rouan M. 2007. Elucidating the role of M2 in the preclinical safety profile of TMC207, abstr PS-71291-11. Proc. 38th World Conf. Lung Health, Cape Town, South Africa.
18. FDA Office of Antimicrobial Products. 28 November 2012. Briefing package, NDA 204-384, Sirturo (bedaquiline 100-mg tablets), for the treatment of adults (-18 years) as part of combination therapy of pulmonary multi-drug-resistant tuberculosis (MDRTB). FDA Anti-Infective Drugs Advisory Committee Meeting. FDA Office of Antimicrobial Products, Silver Spring, MD.
19. Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C, ACTG 5267 Study Team. 2012. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group study A5267. J. Acquir. Immune Defic. Syndr. 59:455-462.
20. Haas DW, Gebretsadik T, Mayo G, Menon UN, Acosta EP, Shintani A, Floyd M, Stein CM, Wilkinson GR. 2009. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans. J. Infect. Dis. 199:872-880.
21. Savic RM, Jonker DM, Kerbusch T, Karlsson MO. 2007. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34:711-726.
22. Cabrera SE, Santos D, Valverde MP, Dominguez-Gil A, Gonzalez F, Luna G, Garcia MJ. 2009. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob. Agents Chemother. 53:2791-2798.
23. Bonate PL. 2011. Pharmacokinetic-pharmacodynamic modeling and simulation, 2nd ed. Springer, New York, NY.
24. Beal S, Sheiner LB, Boeckmann A, Bauer RJ. 2010. NONMEM user's guides (1989-2010). Icon Development Solutions, Ellicott City, MD. 25.
25. Lindbom L, Ribbing J, Jonsson EN. 2004. Perl-speaks-NONMEM (PsN)-a Perl module for NONMEM related programming. Comput. Methods Programs Biomed. 75:85-94.
26. Lindbom L, Pihlgren P, Jonsson EN. 2005. PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79:241-257.
27. Jonsson EN, Karlsson MO. 1999. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64.
28. Keizer RJ, van Benten M, Beijnen JH, Schellens JH, Huitema AD. 2011. Pirana and PCluster: A modeling environment and cluster infrastructure for NONMEM. Comput. Methods Programs Biomed. 101:72-79.
29. Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, Andries K. 2012. Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis. Antimicrob. Agents Chemother. 56:1444-1451.
30. Lounis N, Gevers T, Van Den Berg J, Andries K. 2008. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob. Agents Chemother. 52:3568-3572.
31. Andries K, Gevers T, Lounis N. 2010. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob. Agents Chemother. 54:4540-4544.
32. Cruciani G, Baroni M, Benedetti P, Goracci L, Fortuna GL. 2013. Exposition and reactivity optimization to predict sites of metabolism in chemicals. Drug Discov. Today Technol. 10:e155-e165. http://dx.doi.org/10.1016/ j.ddtec.2012.11.001.
33. Carosati E. Modelling cytochrome p450 binding modes to predict P450 inhibition, metabolic stability and isoform selectivity. Drug Discov. Today Technol., in press.
34. Peresi E, Silva SM, Calvi SA, Marcondes-Machado J. 2008. Cytokines and acute phase serum proteins as markers of inflammatory regression during the treatment of pulmonary tuberculosis. J. Bras. Pneumol. 34: 942-949.
35. Ramakrishnan K, Shenbagarathai R, Kavitha K, Uma A, Balasubramaniam R, Thirumalaikolundusubramanian P. 2008. Serum zinc and albumin levels in pulmonary tuberculosis patients with and without HIV. Jpn. J. Infect. Dis. 61:202-204.
36. McNamara PJ, Alcorn J. 2002. Protein binding predictions in infants. AAPS PharmSci. 4(1):E4. doi:10.1208/ps040104.
37. Smythe W, Khandelwal A, Merle C, Rustomjee R, Gninafon M, Bocar Lo M, Sow OB, Olliaro PL, Lienhardt C, Horton J, Smith P, McIlleron H, Simonsson US. 2012. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob. Agents Chemother. 56:2091-2098.
38. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M. 2009. Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. Antimicrob. Agents Chemother. 53: 2346-2353.
39. Hassan M, Svensson US, Ljungman P, Bjorkstrand B, Olsson H, Bielenstein M, Abdel-Rehim M, Nilsson C, Johansson M, Karlsson MO. 1999. A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br. J. Clin. Pharmacol. 48:669-677.